Center Overview

Our center is a single specialty group practice specializing in hematology and oncology. We have three full time physicians at the practice, which is centrally located between two large cities in southwestern Ohio. All physicians have greater than five years research experience, and we have been participating in clinical trials for over five years at this location.

Clinical Research Experience

Signal Point has served as an investigative site for both treatment and supportive care clinical trials in both hematology and oncology. We have worked with many sponsors and CRO's including Helsinn, Novartis, Taiho, Bayer, Amgen, Ortho Biotech, Genentech, Quintiles. We currently have trials open for enrollment in many types of malignancies and symptom management.

Facility Description

At Signal Point we provide care and treatment to our patients in an outpatient setting. We have infusion rooms as well as private exam and consultation rooms. We are located five minutes from Atrium Medical Center where our physicians have staff priveleges.

Investigator Experience

The Principal Investigator at our site is Nandagopal Vrindavanam, MD. Our Sub-Investigators are Albert Malcolm, MD and Prasad Kudalkar, MD. The clinical research center has experience in conducting Phase I, II, III and IV trials.

Staff Expertise

Signal Point Clinical Research Center, LLC employs four full time, experienced research coordinators. In addition we are supported by the DCOP (Dayton Clinical Oncology Program) personnel in trials conducted through their organization. Our research staff receives annual continuing education through a variety of avenues and maintains appropriate certifications applicable to licensure.

Contact Information

Nandagopal Vrindavanam
MD
Signal Point Clinical Research Center, LLC
235 N. Breiel Blvd.
Middletown, OH 45042
USA
Phone: 513-423-0504
Fax: 513-217-6444
EMail: nvrindavanam@cinci.rr.com

Currently Enrolling Trials

• A Multinational, Randomized, Double-Blind Study comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (VITAL)
• Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.